Your thread is an interesting post about biochemistry studies on PSA. I have been following studies on Abiraterone and how it works as an inhibitor in intertumoural environments. I believe this drug will replace traditional antiandrogens such as Casodex, and that many other drugs in the pipeline will successfully conduct to new ways of treating prostate cancer.
Recently I have posted in another forum a similar approach regarding biochemistry in the fight of prostate cancer. I believe that Genomics is the way to identify the “fundamental causes” of prostate cancer and in doing so, genomics can guide researchers in the development of a new treatment most probably eradicating cancer for good.
The biologist Marion Bussemakers in 1993 discovered the PCA3 (gene) in the urine which is associated to the prostate cancer. The urine test (PCA3) makes part of the group of tests used in the diagnosis of prostate cancer, and it is said to be more accurate than our “friendly” PSA which can give false alarms from enlarged benign hyperplasia.
Genetics also play a role in the risk factors for prostate cancer as it is associated to cases of Pca running in members of the same family or in ethnic groups like Western Europeans, Asians and African Americans. Studies based on genetic principles have identified several genetic variants which are contributors to the risk of developing prostate cancer.
I read that “…There are twentyfive genetic variants that are known to increase the risk of developing prostate cancer: seven on chromosome 8 (five of those in the 8q24 region), two on each of the following chromosomes: 2, 3, 7, 11, 17 and 19 and one on each of the following chromosomes: 4, 5, 6, 10, 22 and X.
This means that if those variants are identified in one’s DNA, most probably that person is prone to develop Pca.
Genetic testing for prostate cancer already exits but companies running the “business” are few and the test is very expensive ($500) when compared to the cost of a PSA, logically, very few patients are doing this test. BBC have announced about a “low cost DNA test” to determine a person’s chances of developing certain inherited diseases. I take this as a light of hope that we may see Genetics replacing PSA
which would be the impulse to studies with sound principles, and therefore, manufacture of directional drugs, identify diets, supplements and behaviors beneficial to attack the cancer. Benlysta
is an inhibitor drug resulting from a study that identified genetic variants linked to the systemic lupus disease. The cause was the biological activity of B-lymphocyte stimulators that contribute to the production of autoantibodies (antibodies that attack the body’s own healthy tissues).
Drugs to “kill” prostate cancer can be produced on the same principle, as well as it could identify foods to combat risk variants, addressing the problem at earlier stages.
All this genomic identification are based in molecular biology regarding the formation, structure, and function of DNA, RNA and proteins, as well as their roles in the transmission of genetic information. From the “Human Genome” system we know that the genetic “information” encoded in a sequence of the DNA strand, passes to molecules of RNA through a process called transcription. RNA acts as a messenger (mRNA) to pass the information to proteins through a process called translation. The message transcribed from the gene is therefore translated into a protein product that is specialized for a particular function based on the instruction stored in the gene.
Knowing the function of each gene becomes essential to the development of molecular markers such as those used in the study you refer regarding PSA. Research funds should be spent in this line of approaches which in my view are in the good direction to find a noninvasive treatment for prostate cancer.
National Cancer Institute has representative videos showing how genetic information is passed and how cancer may develop;
Wishing you a continuous success in your case.